prikaz prve stranice dokumenta Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls
  Download
PDF 388.27 KB
Scientific paper - Original scientific paper
Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls
Endocrine, 48 (2015), 3; 848-855. https://doi.org/10.1007/s12020-014-0413-9
Zibar, Karin; Blaslov, Kristina; Bulum, Tomislav; Knežević Ćuća, Jadranka; Smirčić-Duvnjak, Lea

Cite this document

Zibar, K., Blaslov, K., Bulum, T., Knežević Ćuća, J. & Smirčić Duvnjak, L. (2015). Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls. Endocrine, 48. (3), 848-855. doi: 10.1007/s12020-014-0413-9

Zibar, Karin, et al. "Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls." Endocrine, vol. 48, no. 3, 2015, pp. 848-855. https://doi.org/10.1007/s12020-014-0413-9

Zibar, Karin, Kristina Blaslov, Tomislav Bulum, Jadranka Knežević Ćuća and Lea Smirčić Duvnjak. "Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls." Endocrine 48, no. 3 (2015): 848-855. https://doi.org/10.1007/s12020-014-0413-9

Zibar, K., et al. (2015) 'Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls', Endocrine, 48(3), pp. 848-855. doi: 10.1007/s12020-014-0413-9

Zibar K, Blaslov K, Bulum T, Knežević Ćuća J, Smirčić Duvnjak L. Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls. Endocrine [Internet]. 2015 April [cited 2024 December 31];48(3):848-855. doi: 10.1007/s12020-014-0413-9

K. Zibar, K. Blaslov, T. Bulum, J. Knežević Ćuća and L. Smirčić Duvnjak, "Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls", Endocrine, vol. 48, no. 3, pp. 848-855, April 2015. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:835984. [Accessed: 31 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls
AuthorKarin Zibar
AuthorKristina Blaslov
AuthorTomislav Bulum
AuthorJadranka Knežević Ćuća
AuthorLea Smirčić-Duvnjak
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Fibroblast growth factor-21 (FGF-21) appears to have an important role in glucose and lipid metabolism. FGF-21 secretion is mainly determined by nutritional status. The aim of this study was to measure basal and postprandial FGF-21 and postprandial change of FGF-21 concentration in type 1 diabetes mellitus (T1DM) patients and in healthy controls, and to investigate the differences between the groups. The cross-sectional study included 30 C-peptide negative T1DM patients, median age 37 years (20-59), disease duration 22 years (3-45), and nine healthy controls, median age 30 years (27-47). Basal and postprandial FGF-21 concentrations were measured by ELISA. The associations of FGF-21 with glucose, lipids, and insulin were analyzed. Individuals with T1DM showed significantly lower basal FGF-21 concentration (P=0.046) when compared with healthy controls (median value 28.2 vs 104 pg/mL) and had significantly different postprandial change (∆ 30'-0') of FGF-21 (P=0.006) in comparison with healthy controls (median value -1.1 vs -20.5 pg/mL). The glucose and lipid status did not correlate with FGF-21. In healthy controls, postprandial insulin level correlated with basal FGF-21 (ρ=0.7, P=0.036). Multiple regression analysis showed that they are independently associated after adjustment for confounding factors (β=1.824, P=0.04). We describe the pathological pattern of basal and postprandial change of FGF-21 secretion not associated with glucose, lipid levels, or insulin therapy in patients with T1DM. Since FGF-21 has numerous protective metabolic effects in the experimental model, the lower basal FGF-21 concentration in T1DM patients opens the question about the potential role of recombinant FGF-21 therapy.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleEndocrine
Numberingvol. 48, no. 3, pp. 848-855
p-ISSN1355-008X
DOIhttps://doi.org/10.1007/s12020-014-0413-9
URN:NBNurn:nbn:hr:105:835984
Publication2015-04
Document URLhttps://doi.org/10.1007/s12020-014-0413-9
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 08:15:13